A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)

This trial is comparing two chemotherapy-plus-targeted-therapy treatment plans for women with early-stage, HER2-positive breast cancer that has not spread to the lymph nodes. You may be eligible if... - You are a woman between 18 and 70 years old - You have early-stage HER2-positive breast cancer (the tumor is no larger than 2 cm and has not spread to lymph nodes) - Your surgery was completed within the past 8 weeks - Your heart, blood, liver, and kidney function are within acceptable ranges You may NOT be eligible if... - You received chemotherapy, targeted therapy, radiation, or hormone treatment before surgery - You have cancer that has spread to other parts of the body - You are pregnant or breastfeeding - You have serious heart, lung, liver, or kidney problems - You have uncontrolled high blood pressure or poorly managed diabetes Talk to your doctor to see if this trial is right for you.